Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis
© 2023. Society of Surgical Oncology..
BACKGROUND: Intraperitoneal chemotherapy is promising for gastric cancer with peritoneal metastasis. Although a phase III study failed to show a statistically significant superiority of intraperitoneal paclitaxel combined with S-1 and intravenous paclitaxel, the sensitivity analysis suggested clinical efficacy. Thus, attempts to combine intraperitoneal paclitaxel with other systemic therapies with higher efficacy have been warranted. We sought to explore the efficacy of intraperitoneal paclitaxel with S-1 and cisplatin.
PATIENTS AND METHODS: Gastric cancer patients with peritoneal metastasis were enrolled in the phase II trial. In addition to the established S-1 and cisplatin regimen every 5 weeks, intraperitoneal paclitaxel was administered on days 1, 8, and 22 at a dose of 20 mg/m2. The primary endpoint was overall survival rate at 1 year after treatment initiation. Secondary endpoints were progression-free survival and toxicity.
RESULTS: Fifty-three patients were enrolled and fully evaluated for efficacy and toxicity. The 1-year overall survival rate was 73.6% (95% confidence interval 59.5-83.4%), and the primary endpoint was met. The median survival time was 19.4 months (95% confidence interval, 16.1-24.6 months). The 1-year progression-free survival rate was 49.6% (95% confidence interval, 34.6-62.9%). The incidences of grade 3/4 hematological and non-hematological toxicities were 43% and 47%, respectively. The frequent grade 3/4 toxicities included neutropenia (25%), anemia (30%), diarrhea (13%), and anorexia (17%). Intraperitoneal catheter and implanted port-related complications were observed in four patients. There was one treatment-related death.
CONCLUSIONS: Intraperitoneal paclitaxel combined with S-1 and cisplatin is well tolerated and active in gastric cancer patients with peritoneal metastasis.
| Errataetall: |
CommentIn: Ann Surg Oncol. 2024 Feb;31(2):694-696. - PMID 37684365 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Annals of surgical oncology - 31(2024), 2 vom: 11. Feb., Seite 735-743 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kobayashi, Daisuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 12.03.2024 published: Print-Electronic CommentIn: Ann Surg Oncol. 2024 Feb;31(2):694-696. - PMID 37684365 Citation Status MEDLINE |
|---|
| doi: |
10.1245/s10434-023-14240-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364436743 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364436743 | ||
| 003 | DE-627 | ||
| 005 | 20240313233800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1245/s10434-023-14240-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM364436743 | ||
| 035 | |a (NLM)37952018 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kobayashi, Daisuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Surg Oncol. 2024 Feb;31(2):694-696. - PMID 37684365 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Society of Surgical Oncology. | ||
| 520 | |a BACKGROUND: Intraperitoneal chemotherapy is promising for gastric cancer with peritoneal metastasis. Although a phase III study failed to show a statistically significant superiority of intraperitoneal paclitaxel combined with S-1 and intravenous paclitaxel, the sensitivity analysis suggested clinical efficacy. Thus, attempts to combine intraperitoneal paclitaxel with other systemic therapies with higher efficacy have been warranted. We sought to explore the efficacy of intraperitoneal paclitaxel with S-1 and cisplatin | ||
| 520 | |a PATIENTS AND METHODS: Gastric cancer patients with peritoneal metastasis were enrolled in the phase II trial. In addition to the established S-1 and cisplatin regimen every 5 weeks, intraperitoneal paclitaxel was administered on days 1, 8, and 22 at a dose of 20 mg/m2. The primary endpoint was overall survival rate at 1 year after treatment initiation. Secondary endpoints were progression-free survival and toxicity | ||
| 520 | |a RESULTS: Fifty-three patients were enrolled and fully evaluated for efficacy and toxicity. The 1-year overall survival rate was 73.6% (95% confidence interval 59.5-83.4%), and the primary endpoint was met. The median survival time was 19.4 months (95% confidence interval, 16.1-24.6 months). The 1-year progression-free survival rate was 49.6% (95% confidence interval, 34.6-62.9%). The incidences of grade 3/4 hematological and non-hematological toxicities were 43% and 47%, respectively. The frequent grade 3/4 toxicities included neutropenia (25%), anemia (30%), diarrhea (13%), and anorexia (17%). Intraperitoneal catheter and implanted port-related complications were observed in four patients. There was one treatment-related death | ||
| 520 | |a CONCLUSIONS: Intraperitoneal paclitaxel combined with S-1 and cisplatin is well tolerated and active in gastric cancer patients with peritoneal metastasis | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Kodera, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Ryoji |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Fushida, Sachio |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Kozo |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Shugo |e verfasserin |4 aut | |
| 700 | 1 | |a Yabusaki, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kusumoto, Tetsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Arigami, Takaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hidemura, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Omori, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Hirono, Yasuo |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Jeong Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Imamura, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Koki |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Hirakawa, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishigami, Hironori |e verfasserin |4 aut | |
| 700 | 1 | |a Kitayama, Joji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of surgical oncology |d 1995 |g 31(2024), 2 vom: 11. Feb., Seite 735-743 |w (DE-627)NLM074734997 |x 1534-4681 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:2 |g day:11 |g month:02 |g pages:735-743 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1245/s10434-023-14240-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 2 |b 11 |c 02 |h 735-743 | ||